Corcept Therapeutics to Present Data at the American Association of Cancer Research Annual Meeting
“Excessive cortisol in patients with adrenal cancer causes Cushing’s syndrome and may also blunt the efficacy of immunotherapeutic agents such as checkpoint inhibitors,” said
Suppression of Tumor Immune Activity in Adrenocortical Carcinoma with Excess Glucocorticoid
- Session Title:
Late-Breaking Research : Clinical Research 1 / Endocrinology - Session Type: Poster session
- Poster No: LB-130
- Location: Virtual meeting
- Presentation Available Online: Beginning
June 22 (meeting registration required)
About Relacorilant
Relacorilant is a non-steroidal, selective modulator of the glucocorticoid receptor, the receptor for cortisol which is activated when cortisol levels are high. Relacorilant does not bind to the body's other hormone receptors, including the progesterone receptor. Corcept is studying relacorilant as a potential treatment for a variety of serious disorders, including Cushing’s syndrome and advanced adrenal, ovarian and pancreatic cancer. Relacorilant is proprietary to Corcept and is protected by composition of matter and method of use patents. Relacorilant has received orphan drug designation in
About
Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol. Korlym® was the first drug approved by the
CONTACT:
Director, Investor Relations
650-684-8725
cjames@corcept.com
www.corcept.com
_______________
1 For additional information, see Clinicaltrials.gov (trial identifier: NCT04373265).
Source: Corcept Therapeutics Incorporated